Company Profiles

driven by the PitchBook Platform

Annexon Bioscience

Annexon Bioscience
2011 FOUNDED
PRIVATE STATUS
Series B LATEST DEAL TYPE
$44M LATEST DEAL AMOUNT
$79M TOTAL AMOUNT RAISED
6 INVESTORS
Description

Developer of novel disease-modifying drugs to treat neurodegenerative disorders. The company is developing a pipeline of classical complement pathway inhibitors focused on therapies for complement-mediated loss of nerve connections in the brain, as occurs in Alzheimer's disease and Huntington's disease, as well as in retinal cells, as seen in glaucoma.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
280 Utah Avenue
Suite 110
South San Francisco, CA 94080
United States

+1 (650) 822-5500
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Annexon Bioscience’s full profile, request a free trial.

Annexon Bioscience Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 23-Jun-2016 $44M $79M 000.00 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A1) 15-Dec-2014 0000 0000 000.00 Completed Startup
1. Early Stage VC (Series A) $1000k $1000k $11M Completed Startup
To view this company’s complete deal history including valuation and funding request access »

Annexon Bioscience Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A1 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 1,015,434 $0.001000 $0.98 $0.98 1x $0.98 1.48%
To view this company’s complete Cap Table request access »

Annexon Bioscience Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Clarus Ventures Venture Capital Minority 000 0000 000000 0
Correlation Ventures Venture Capital Minority 000 0000 000000 0
JLABS Accelerator/Incubator 000 0000 000000 0
New Enterprise Associates Venture Capital Minority 000 0000 000000 0
Novartis Venture Fund Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Annexon Bioscience Executive Team (5)

Name Title Board
Seat
Contact
Info
Douglas Love JD Chief Executive Officer, President & Board Member
Ted Yednock Ph.D Chief Scientific Officer
Ben Barres Ph.D Co-Founder
Susan Kramer Vice President, Product Development
Mario Saltarelli Ph.D Chief Medical Officer

You’re viewing 5 of 5 executives.

Annexon Bioscience Board Members (9)

Name Representing Role Since Contact
Info
Arnon Rosenthal Ph.D Self Co-Founder & Chairman 000 0000
Campbell Murray MD Novartis Venture Fund Board Member 000 0000
Douglas Love JD Annexon Bioscience Chief Executive Officer, President & Board Member 000 0000
Emmett Cunningham Jr. Clarus Ventures Board Member 000 0000
Frank Torti MD New Enterprise Associates Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »